The FDA revised its emergency use authorization for EVUSHELD™, tixagevimab co-packaged with cilgavimab. The initial dose authorized has been changed to 600 mg for pre-exposure prevention of COVID-19.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
